SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:DiVA.org:liu-205176"
 

Search: id:"swepub:oai:DiVA.org:liu-205176" > The road to tailore...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Uijterwijk, Bas A.Fdn Poliambulanza Ist Osped, Italy; Univ Amsterdam, Netherlands; Canc Ctr Amsterdam, Netherlands (author)

The road to tailored adjuvant chemotherapy for all four non-pancreatic periampullary cancers: An international multimethod cohort study

  • Article/chapterEnglish2024

Publisher, publication year, extent ...

  • 2024
  • SPRINGERNATURE,2024
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-205176
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-205176URI
  • https://doi.org/10.1038/s41416-024-02692-wDOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background: Despite differences in tumour behaviour and characteristics between duodenal adenocarcinoma (DAC), the intestinal (AmpIT) and pancreatobiliary (AmpPB) subtype of ampullary adenocarcinoma and distal cholangiocarcinoma (dCCA), the effect of adjuvant chemotherapy (ACT) on these cancers, as well as the optimal ACT regimen, has not been comprehensively assessed. This study aims to assess the influence of tailored ACT on DAC, dCCA, AmpIT, and AmpPB. Patients and methods: Patients after pancreatoduodenectomy for non-pancreatic periampullary adenocarcinoma were identified and collected from 36 tertiary centres between 2010 - 2021. Per non-pancreatic periampullary tumour type, the effect of adjuvant chemotherapy and the main relevant regimens of adjuvant chemotherapy were compared. The primary outcome was overall survival (OS). Results: The study included a total of 2866 patients with DAC (n = 330), AmpIT (n = 765), AmpPB (n = 819), and dCCA (n = 952). Among them, 1329 received ACT, and 1537 did not. ACT was associated with significant improvement in OS for AmpPB (P = 0.004) and dCCA (P < 0.001). Moreover, for patients with dCCA, capecitabine mono ACT provided the greatest OS benefit compared to gemcitabine (P = 0.004) and gemcitabine - cisplatin (P = 0.001). For patients with AmpPB, no superior ACT regime was found (P > 0.226). ACT was not associated with improved OS for DAC and AmpIT (P = 0.113 and P = 0.445, respectively). Discussion: Patients with resected AmpPB and dCCA appear to benefit from ACT. While the optimal ACT for AmpPB remains undetermined, it appears that dCCA shows the most favourable response to capecitabine monotherapy. Tailored adjuvant treatments are essential for enhancing prognosis across all four non-pancreatic periampullary adenocarcinomas.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Lemmers, Daniel H.Fdn Poliambulanza Ist Osped, Italy; Univ Amsterdam, Netherlands; Canc Ctr Amsterdam, Netherlands (author)
  • Ghidini, MicheleFdn IRCCS Ca Granda Osped Maggiore Policlin, Italy (author)
  • Wilmink, Johanna W.Canc Ctr Amsterdam, Netherlands; Univ Amsterdam, Netherlands (author)
  • Zaniboni, AlbertoFdn Poliambulanza, Italy (author)
  • Fusai, Giuseppe KitoRoyal Free London NHS Fdn Trust, England (author)
  • Zerbi, AlessandroHumanitas Univ, Italy; IRCCS Humanitas Res Hosp, Italy (author)
  • Koerkamp, Bas GrootErasmus MC, Netherlands (author)
  • Luyer, MishaCatharina Hosp, Netherlands (author)
  • Ghorbani, PoyaKarolinska Inst, Sweden (author)
  • Salvia, RobertoUniv Hosp Verona, Italy (author)
  • White, StevenNewcastle Tyne Hosp NHS Fdn Trust, England (author)
  • Ielpo, BenedettoHosp Del Mar, Spain (author)
  • Goh, Brian K. P.Duke Natl Univ Singapore, Singapore (author)
  • Boggi, UgoPisa Univ Hosp, Italy (author)
  • Kazemier, GeertCanc Ctr Amsterdam, Netherlands; Amsterdam UMC, Netherlands (author)
  • House, Michael G.Indiana Univ Sch Med, IN USA (author)
  • Mavroeidis, Vasileios K.Royal Marsden Hosp, England; Oxford Univ Hosp NHS Fdn Trust, England (author)
  • Björnsson, BergthorLinköpings universitet,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Kirurgiska kliniken US(Swepub:liu)berbj34 (author)
  • Mazzola, MicheleASST Grande Osped Metropolitano Niguarda, Italy (author)
  • Serradilla, MarioMiguel Servet Univ Hosp, Spain (author)
  • Korkolis, DimitrisHellen Anticanc Hosp Saint Savvas, Greece (author)
  • Alseidi, AdnanVirginia Mason, WA USA (author)
  • Roberts, Keith J.Univ Birmingham, England (author)
  • Soonawalla, ZahirOxford Univ Hosp NHS Fdn Trust, England (author)
  • Pessaux, PatrickNouvel Hop Civil NHC, France (author)
  • Fisher, William E.Baylor Coll Med, TX USA (author)
  • Koek, SharniceFiona Stanley Hosp, Australia (author)
  • Kent, Tara S.Beth Israel Deaconess Med Ctr, MA USA (author)
  • Vladimirov, MiljanaParacelsus Med Univ Nurnberg, Germany (author)
  • Bolm, LouisaUniv Med Ctr Schleswig Holstein, Germany (author)
  • Jamieson, NigelGlasgow Royal Infirm, Scotland (author)
  • Dalla Valle, RaffaeleUniv Hosp Parma, Italy (author)
  • Kleeff, JorgMartin Luther Univ Halle Wittenberg, Germany (author)
  • Mazzotta, AlessandroInst Mutualiste Montsouris, France (author)
  • Munoz, Miguel Angel SuarezInst Mutualiste Montsouris, France (author)
  • Cabus, Santiago SanchezHosp Santa Creu & Sant Pau, Spain (author)
  • Ball, Chad G.Univ Calgary, Canada (author)
  • Berger, Adam C.Jefferson Med Coll, PA USA (author)
  • Ferarri, ClarissaFdn Poliambulanza Ist Osped, Italy (author)
  • Besselink, Marc G.Univ Amsterdam, Netherlands; Canc Ctr Amsterdam, Netherlands (author)
  • Hilal, Mohammed AbuFdn Poliambulanza Ist Osped, Italy (author)
  • Fdn Poliambulanza Ist Osped, Italy; Univ Amsterdam, Netherlands; Canc Ctr Amsterdam, NetherlandsFdn IRCCS Ca Granda Osped Maggiore Policlin, Italy (creator_code:org_t)

Related titles

  • In:British Journal of Cancer: SPRINGERNATURE0007-09201532-1827

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view